Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1988 1
1991 1
1996 1
2001 1
2006 1
2014 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Unresectable Salivary Gland Squamous Cell Carcinoma"
Page 1
A rationale for chemoradiation (vs radiotherapy) in salivary gland cancers? On behalf of the REFCOR (French rare head and neck cancer network).
Cerda T, Sun XS, Vignot S, Marcy PY, Baujat B, Baglin AC, Ali AM, Testelin S, Reyt E, Janot F, Thariat J. Cerda T, et al. Crit Rev Oncol Hematol. 2014 Aug;91(2):142-58. doi: 10.1016/j.critrevonc.2014.02.002. Epub 2014 Feb 16. Crit Rev Oncol Hematol. 2014. PMID: 24636481 Review.
BACKGROUND: Salivary gland carcinomas constitute a heterogeneous group of tumors, with over 20 histological subtypes of various prognoses. ...Concurrent chemotherapy is sometimes advocated in routine practice based on criteria extrapolated from squamous ce …
BACKGROUND: Salivary gland carcinomas constitute a heterogeneous group of tumors, with over 20 histological subtypes of variou …
Near-infrared photoimmunotherapy for salivary duct carcinoma.
Makino T, Sato Y, Uraguchi K, Naoi Y, Fukuda Y, Ando M. Makino T, et al. Auris Nasus Larynx. 2024 Apr;51(2):323-327. doi: 10.1016/j.anl.2023.09.006. Epub 2023 Sep 27. Auris Nasus Larynx. 2024. PMID: 37775468
In Japan, near-infrared photoimmunotherapy (NIR-PIT) was introduced in 2021 as a treatment option for unresectable recurrent head and neck cancer. The treatment targets the epidermal growth factor receptor (EGFR), which is overexpressed in 80-90 % of head and neck squam …
In Japan, near-infrared photoimmunotherapy (NIR-PIT) was introduced in 2021 as a treatment option for unresectable recurrent head and …
Chemotherapy for salivary gland cancer.
Kaplan MJ, Johns ME, Cantrell RW. Kaplan MJ, et al. Otolaryngol Head Neck Surg. 1986 Sep;95(2):165-70. doi: 10.1177/019459988609500206. Otolaryngol Head Neck Surg. 1986. PMID: 3035459
Ten patients with recurrent, metastatic, or unresectable salivary gland tumors were treated with combination chemotherapy, primarily with cisplatin, doxorubicin hydrochloride (Adriamycin), and cyclophosphamide, or cisplatin with 5-fluorouracil. ...Adenocarcin …
Ten patients with recurrent, metastatic, or unresectable salivary gland tumors were treated with combination chemothera …
Curative high-dose reirradiation for patients with recurrent head and neck adenoid cystic carcinomas: outcomes and analysis of patterns of failure.
Mahé M, Beddok A, Goudjil F, Ala Eddine C, Bolle S, Champion L, Feuvret L, Herman P, Zefkili S, Choussy O, Le Tourneau C, Dendale R, Buvat I, Sauvaget E, Créhange G, Calugaru V. Mahé M, et al. Int J Radiat Biol. 2024;100(1):79-86. doi: 10.1080/09553002.2023.2242934. Epub 2023 Aug 21. Int J Radiat Biol. 2024. PMID: 37526368
BACKGROUND: To investigate the outcomes of patients who underwent curative reirradiation (reRT), with intensity-modulated radiation therapy (IMRT) or proton therapy (PT) for unresectable recurrent or second primary head and neck adenoid cystic carcinoma (HNACC). ... …
BACKGROUND: To investigate the outcomes of patients who underwent curative reirradiation (reRT), with intensity-modulated radiation therapy …
Stage 4 squamous cell carcinoma of the tongue in a child: complete response to chemoradiotherapy.
Soni S, Radel E, Smith RV, Edelman M, Sattenberg R, Wadler S, Beitler JJ. Soni S, et al. J Pediatr Hematol Oncol. 2001 Dec;23(9):612-5. doi: 10.1097/00043426-200112000-00012. J Pediatr Hematol Oncol. 2001. PMID: 11902307
This report describes a complete response to a chemoradiotherapy regimen in a child with an advanced and unresectable squamous cell carcinoma of the tongue. An 8-year-old girl had stage 4 squamous cell carcinoma of the tongue (T4N2 …
This report describes a complete response to a chemoradiotherapy regimen in a child with an advanced and unresectable squamous …
Photon irradiation of unresectable carcinomas of salivary glands.
Wang CC, Goodman M. Wang CC, et al. Int J Radiat Oncol Biol Phys. 1991 Aug;21(3):569-76. doi: 10.1016/0360-3016(91)90672-q. Int J Radiat Oncol Biol Phys. 1991. PMID: 1651301
The patient material consists of a total of 24 patients, 9 with carcinoma arising from the parotid gland and 15 with lesions in the minor salivary glands, mainly the oral cavity and oropharynx. ...The present series showed excellent local control and s …
The patient material consists of a total of 24 patients, 9 with carcinoma arising from the parotid gland and 15 with lesions i …
Neutron vs photon irradiation of inoperable salivary gland tumors: results of an RTOG-MRC Cooperative Randomized Study.
Griffin TW, Pajak TF, Laramore GE, Duncan W, Richter MP, Hendrickson FR, Maor MH. Griffin TW, et al. Int J Radiat Oncol Biol Phys. 1988 Nov;15(5):1085-90. doi: 10.1016/0360-3016(88)90188-5. Int J Radiat Oncol Biol Phys. 1988. PMID: 2846479 Clinical Trial.
A total of 32 patients with inoperable, recurrent or unresectable malignant salivary gland tumors were entered on a randomized RTOG/MRC study comparing fast neutron radiotherapy with conventional photon radiotherapy. Twenty-five patients were entered f …
A total of 32 patients with inoperable, recurrent or unresectable malignant salivary gland tumors were entered on a …
Present status of fast neutron therapy in Asian countries.
Tsunemoto H, Yoo SY. Tsunemoto H, et al. Bull Cancer Radiother. 1996;83 Suppl:93s-100s. doi: 10.1016/0924-4212(96)84891-2. Bull Cancer Radiother. 1996. PMID: 8949758
The results showed that local control rates were 79% (19/24), 53% (14/26), and 89.3% (50/56) for carcinoma of the salivary gland, osteogenic sarcoma and carcinoma of the prostate, while complications for those were found to be 8.8, 8.3 and 17.8%, respe …
The results showed that local control rates were 79% (19/24), 53% (14/26), and 89.3% (50/56) for carcinoma of the salivary …
Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naive locally advanced upper aerodigestive malignancy.
Langer CJ, Duffy K, Horwitz EM, Litwin S, Rosvold E, Schol J, Keenan E, Nicolaou N, Friedman CD, Ridge JA. Langer CJ, et al. Cancer Invest. 2006 Mar;24(2):164-73. doi: 10.1080/07357900500524421. Cancer Invest. 2006. PMID: 16537186 Clinical Trial.
PURPOSE: Phase I study to determine the maximally tolerated dose (MTD) of cisplatin (cDDP), paclitaxel (P), and concurrent split course hyperfractionated (BID) RT in advanced squamous cell carcinoma of the head and neck (SCCHN) and other upper aerodigestive t …
PURPOSE: Phase I study to determine the maximally tolerated dose (MTD) of cisplatin (cDDP), paclitaxel (P), and concurrent split course hype …